DDInter1266 DDInter519
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes , , and ), dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.
Naproxen {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Prasugrel
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Naproxen {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Naproxen {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Prasugrel
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Naproxen {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Naproxen {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Naproxen {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Naproxen {u} (Compound) causes {v} (Side Effect) Haematochezia
Haematochezia {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Pazopanib {u} may lead to a major life threatening interaction when taken with {v} Dexlansoprazole
Naproxen {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Methotrexate
Methotrexate {u} may lead to a major life threatening interaction when taken with {v} Dexlansoprazole
Naproxen {u} (Compound) causes {v} (Side Effect) Haematochezia
Haematochezia {u} (Side Effect) is caused by {v} (Compound) Erlotinib
Erlotinib {u} may lead to a major life threatening interaction when taken with {v} Dexlansoprazole
Naproxen {u} (Compound) causes {v} (Side Effect) Gastrointestinal haemorrhage
Gastrointestinal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Naproxen (Compound) binds ALB (Gene) and ALB (Gene) is bound by Prasugrel (Compound) and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Naproxen (Compound) binds ALB (Gene) and ALB (Gene) is bound by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Naproxen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound) and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Naproxen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Naproxen (Compound) binds ALB (Gene) and ALB (Gene) is bound by Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Naproxen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Naproxen (Compound) causes Haematochezia (Side Effect) and Haematochezia (Side Effect) is caused by Pazopanib (Compound) and Pazopanib may lead to a major life threatening interaction when taken with Dexlansoprazole
Naproxen (Compound) binds ALB (Gene) and ALB (Gene) is bound by Methotrexate (Compound) and Methotrexate may lead to a major life threatening interaction when taken with Dexlansoprazole
Naproxen (Compound) causes Haematochezia (Side Effect) and Haematochezia (Side Effect) is caused by Erlotinib (Compound) and Erlotinib may lead to a major life threatening interaction when taken with Dexlansoprazole
Naproxen (Compound) causes Gastrointestinal haemorrhage (Side Effect) and Gastrointestinal haemorrhage (Side Effect) is caused by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole